CN104840563A - Traditional Chinese medicine preparation for treating metastatic bone cancer - Google Patents
Traditional Chinese medicine preparation for treating metastatic bone cancer Download PDFInfo
- Publication number
- CN104840563A CN104840563A CN201510243477.7A CN201510243477A CN104840563A CN 104840563 A CN104840563 A CN 104840563A CN 201510243477 A CN201510243477 A CN 201510243477A CN 104840563 A CN104840563 A CN 104840563A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- parts
- medicine preparation
- bone cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine preparation for treating metastatic bone cancer. Metastatic bone cancer refers to a secondary tumor produced by a malignant tumor which primarily occurs in a certain organ and then is transferred to a bone through a blood circulation or lymphatic system, and belongs to the range of bone impediments, yin arthralgia and the like. The invention selects traditional Chinese medicines Schisandra fruit, Cynanchum wallichii Wight, Embelia laeta, Uncaria tomentosa root, Indigofera mengtzeana, Chinese astilbe rhizome, Ophiorrhiza mungos, Schisandra propinqua, Henry clematis root and grass fern which are decocted with water into decoction. As proved by clinical tests, the curative effect is remarkable and the traditional Chinese medicine preparation for treating metastatic bone cancer is worthy of being clinically popularized.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine preparation for the treatment of metastatic bone cancer.
Background technology
Metastatic bone cancer refers to that the malignant tumor that is primary in body organ transfers to by blood circulation or lymphsystem the secondary tumor that skeleton produces, belong to the category such as the traditional Chinese medical science " rheumatism involving the bone ", " YIN arthralgia ", it is the common complication of malignant tumor, each malignant tumor all can transfer to bone, wherein the highest with breast carcinoma, thyroid carcinoma, bone metastases of lung cancer incidence rate.Although the Comprehensive Treatments such as operation, Radiotherapy chemotherapy, internal-radiation therapy, bone resorption inhibitor, endocrine are extensive use achieve the curative effect of affirmative clinically, but late result is not obvious, and side effect is comparatively large, such as anemia, appetite decline, gastrointestinal reaction, weak etc.For the treatment of metastatic bone cancer, the traditional Chinese medical science is emphasized from entirety, the balance of adjustment body negative and positive, QI and blood, function, according to different clinical symptoms, and treating both the principal and secondary aspects of a disease, strengthening vital QI to eliminate pathogenic factors.The advantage of Chinese medicine primary disease is both can be anticancer, again can pain relieving, and the immunologic function of patient can be improved well, improve resistance against diseases, reduce the consumption of analgesic drug product or alleviate the untoward reaction of analgesic drug product, and the toxic and side effects of Radiotherapy chemotherapy can be reduced, obviously improve the quality of life of patients with terminal.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine preparation for the treatment of metastatic bone cancer.
The object of the invention is to be achieved through the following technical solutions, the Chinese medicine preparation of this treatment metastatic bone cancer is made up of the Chinese medicine of following weight portion: Fructus Schisandrae lancifoliae 4-8 part, Radix cynanchi wallichii 20-40 part, Fructus embeliae laetae 7-10 part, Radix Uncariae rhynchophyllae 10-20 part, Indigofera mentzeana Craib 3-6 part, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 8-12 part, Herba ophiorrhizae japonicae 10-20 part, Radix seu Caulis Schisandrae Sinensis 7-12 part, Radix Clematidis Henryi 3-6 part, Vittaria fudzinoi Mak. 15-25 part.
Preferably, Fructus Schisandrae lancifoliae 6 parts, Radix cynanchi wallichii 30 parts, Fructus embeliae laetae 8 parts, Radix Uncariae rhynchophyllae 15 parts, Indigofera mentzeana Craib 5 parts, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 10 parts, Herba ophiorrhizae japonicae 15 parts, Radix seu Caulis Schisandrae Sinensis 10 parts, Radix Clematidis Henryi 5 parts, Vittaria fudzinoi Mak. 20 parts.
Preparation method decocting makes decoction.
Fang Zhong: Fructus Schisandrae lancifoliae benefit essence is reinforced the kidney; Radix cynanchi wallichii Bu Shen Zhuang waist, bone and muscle strengthening; Fructus embeliae laetae is strong enriches blood; Radix Uncariae rhynchophyllae relaxing muscles and tendons and activating QI and blood in the collateral, clearing heat for detumescence; Indigofera mentzeana Craib relaxing muscles and tendons and activating QI and blood in the collateral, easing pain and diminishing inflammation; Radix astilbes chinensis (Rhizoma Astilbes Chinensis) blood circulation promoting and blood stasis dispelling, analgesic antidotal; Herba ophiorrhizae japonicae promoting blood circulation to remove blood stasis; Radix seu Caulis Schisandrae Sinensis promoting blood circulation to remove blood stasis, promoting the circulation of QI to relieve pain; Radix Clematidis Henryi promoting the circulation of QI to relieve pain, anti inflammatory blood quickening; Vittaria fudzinoi Mak. promoting the circulation of QI to relieve pain, to invigorate blood circulation.
Clinical data
1, physical data chooses medical metastatic bone cancer patient 30 example of my Out-patient Department, and all patients have all made a definite diagnosis primary malignant neoplasm through histopathology or cytopathology, are diagnosed as metastatic bone cancer through iconography, and choose in strict accordance with case inclusive criteria.Clinical in patient assessment's sequencing and the compliance taking Chinese medicine, include 30 routine patients in treatment group and matched group respectively, each group 15 example, two groups of patients there are no significant in the aspect such as how many, the Pain Grading of age, metastasis before the treatment difference (P > 0.05).
2, treatment and care method matched group give in becoming a fine day according to treatment (manufacturing enterprise: Jiangsu Zhengda Tianqing Drug Industry Co., Ltd of the Qin; Authentication code: the accurate word HZ0041346 of traditional Chinese medicines; Adopted name: zoledronic acid injection) treatment, each 4mg (1), instil with 100ml 0.9% sodium chloride injection dilution posterior vein, the instillation time is no less than 15 minutes.Within every 4 weeks, be administered once.Treatment group takes Chinese medicine preparation of the present invention, take Fructus Schisandrae lancifoliae 6g, Radix cynanchi wallichii 30g, Fructus embeliae laetae 8g, Radix Uncariae rhynchophyllae 15g, Indigofera mentzeana Craib 5g, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 10g, Herba ophiorrhizae japonicae 15g, Radix seu Caulis Schisandrae Sinensis 10g, Radix Clematidis Henryi 5g, Vittaria fudzinoi Mak. 20g, day potion, decocting twice, at twice decoction being taken warmly.Treat 3 months continuously for above two groups, treatments period is without analgesic.Treatments period advises patient to adhere to taking medicine, and be careful in one's diet daily life, and give psychological counseling in good time, to alleviate mental burden and psychology fear.
3, the Comprehensive Clinical curative effect of criterion of therapeutical effect main detection two groups of patients, comprises related symptoms sign, Pain Grading, peripheral hemogram, hepatic and renal function, and blood calcium and quality of life improve situation.
4, therapeutic outcome treatment group clinical efficacy is higher than matched group.Treatment group is 86.7% improving effective percentage in pain, and matched group is 53.3%; Treatment group effective percentage in the generation of minimizing bone dependent event is 93.3%, and matched group is 60.0%; It is 66.7% that treatment group reduces relapse and metastasis aspect effective percentage, and matched group is 40.0%; It is 80% that treatment group improves effective percentage in situation in quality of life, and matched group is 33.3%; Above all through statistical procedures, P < 0.05, has statistical significance, and peripheral hemogram after testing, hepatic and renal functions etc. have no obvious toxic-side effects.Whole research process, takes off group without case.
Detailed description of the invention
Embodiment one: take Fructus Schisandrae lancifoliae 6g, Radix cynanchi wallichii 30g, Fructus embeliae laetae 8g, Radix Uncariae rhynchophyllae 15g, Indigofera mentzeana Craib 5g, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 10g, Herba ophiorrhizae japonicae 15g, Radix seu Caulis Schisandrae Sinensis 10g, Radix Clematidis Henryi 5g, Vittaria fudzinoi Mak. 20g, decocting makes decoction.
Embodiment two: take Fructus Schisandrae lancifoliae 8g, Radix cynanchi wallichii 20g, Fructus embeliae laetae 10g, Radix Uncariae rhynchophyllae 10g, Indigofera mentzeana Craib 6g, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 8g, Herba ophiorrhizae japonicae 20g, Radix seu Caulis Schisandrae Sinensis 7g, Radix Clematidis Henryi 6g, Vittaria fudzinoi Mak. 15g, decocting makes decoction.
Embodiment three: take Fructus Schisandrae lancifoliae 4g, Radix cynanchi wallichii 40g, Fructus embeliae laetae 7g, Radix Uncariae rhynchophyllae 20g, Indigofera mentzeana Craib 3g, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 12g, Herba ophiorrhizae japonicae 10g, Radix seu Caulis Schisandrae Sinensis 12g, Radix Clematidis Henryi 3g, Vittaria fudzinoi Mak. 25g, decocting makes decoction.
Claims (2)
1. treat a Chinese medicine preparation for metastatic bone cancer, it is characterized in that this Chinese medicine preparation is made up of the Chinese medicine of following weight portion: Fructus Schisandrae lancifoliae 4-8 part, Radix cynanchi wallichii 20-40 part, Fructus embeliae laetae 7-10 part, Radix Uncariae rhynchophyllae 10-20 part, Indigofera mentzeana Craib 3-6 part, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 8-12 part, Herba ophiorrhizae japonicae 10-20 part, Radix seu Caulis Schisandrae Sinensis 7-12 part, Radix Clematidis Henryi 3-6 part, Vittaria fudzinoi Mak. 15-25 part.
2. a kind of Chinese medicine preparation for the treatment of metastatic bone cancer as claimed in claim 1, is characterized in that this Chinese medicine preparation is made up of the Chinese medicine of following weight portion: Fructus Schisandrae lancifoliae 6 parts, Radix cynanchi wallichii 30 parts, Fructus embeliae laetae 8 parts, Radix Uncariae rhynchophyllae 15 parts, Indigofera mentzeana Craib 5 parts, Radix astilbes chinensis (Rhizoma Astilbes Chinensis) 10 parts, Herba ophiorrhizae japonicae 15 parts, Radix seu Caulis Schisandrae Sinensis 10 parts, Radix Clematidis Henryi 5 parts, Vittaria fudzinoi Mak. 20 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510243477.7A CN104840563A (en) | 2015-05-09 | 2015-05-09 | Traditional Chinese medicine preparation for treating metastatic bone cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510243477.7A CN104840563A (en) | 2015-05-09 | 2015-05-09 | Traditional Chinese medicine preparation for treating metastatic bone cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104840563A true CN104840563A (en) | 2015-08-19 |
Family
ID=53840809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510243477.7A Pending CN104840563A (en) | 2015-05-09 | 2015-05-09 | Traditional Chinese medicine preparation for treating metastatic bone cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104840563A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0153468B1 (en) * | 1988-10-31 | 1998-12-01 | 리챠드 지 워터맨 | Chelants possessing ortho ligating functionality and complex thereof |
| CN201524153U (en) * | 2009-11-17 | 2010-07-14 | 孙平 | Limb middle-piece marrow internal lock |
| CN102335237A (en) * | 2011-10-13 | 2012-02-01 | 尹立焱 | Plaster for treating cancer pain and preparation method thereof |
-
2015
- 2015-05-09 CN CN201510243477.7A patent/CN104840563A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0153468B1 (en) * | 1988-10-31 | 1998-12-01 | 리챠드 지 워터맨 | Chelants possessing ortho ligating functionality and complex thereof |
| CN201524153U (en) * | 2009-11-17 | 2010-07-14 | 孙平 | Limb middle-piece marrow internal lock |
| CN102335237A (en) * | 2011-10-13 | 2012-02-01 | 尹立焱 | Plaster for treating cancer pain and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 郭全等: "肺癌骨转移的治疗", 《中国临床医生》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102697899A (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| CN103041312A (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN103536858B (en) | Medicine for treating rheumatoid arthritis | |
| CN105816806A (en) | Traditional Chinese medicine preparation for treating thyroid nodule | |
| CN102861262B (en) | Traditional Chinese medicine composition for treating esophageal cancer | |
| CN101983644A (en) | Medicament for treating sequelae of apoplexy | |
| CN102552402B (en) | External medicine for treating rheumatic diseases | |
| CN105434972A (en) | Traditional Chinese medicine composition for treating breast hyperplasia | |
| CN102920933B (en) | Chinese medicinal preparation for treating chronic obstructive pulmonary diseases | |
| CN104587339A (en) | Traditional Chinese medicine soaking agent for treating chemotherapy-related peripheral nerve toxicity | |
| CN102836241B (en) | Traditional Chinese medicine combination for treating neck shoulder lumbocrural pains caused by spinal degenerative change | |
| CN114028507A (en) | Preparation method of traditional Chinese medicine for treating lumbago | |
| CN103432560B (en) | External medicament for treating simple obesity and preparation method thereof | |
| CN104840563A (en) | Traditional Chinese medicine preparation for treating metastatic bone cancer | |
| CN103083387A (en) | Congestion-eliminating pain-relieving plaster | |
| CN101961455A (en) | Traditional Chinese medicine for treating chronic colitis disease | |
| CN103393909A (en) | Chinese medicinal preparation for treating biliary calculus with cholecystitis | |
| CN103127295B (en) | One is treated leukemic Chinese medicine | |
| CN107050333B (en) | Granules for treating ankylosing spondylitis | |
| CN105311503A (en) | Traditional Chinese medicine fuming and washing agent for treating chemotherapy surrounding related toxicities | |
| CN104800693B (en) | A kind of Chinese medicine composition for treating lung cancer | |
| CN104800571A (en) | Traditional Chinese medicine plaster for treating dyspnea symptom of patient with lung cancer | |
| CN104435979B (en) | A kind of medicine for treating rheumatic lumbocrural pain pain | |
| CN104491504A (en) | Traditional Chinese medicine preparation for treating pleural effusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150819 |